BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10445888)

  • 1. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children.
    Schmiegelow M; Hertz H; Schmiegelow K; Holm K; Müller J
    J Pediatr Hematol Oncol; 1999; 21(4):268-73. PubMed ID: 10445888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The assessment of plasma levels of insulin-like growth factor (IGF-I) and binding protein (IGFBP-3) during the maintenance therapy and after remissionof acute lymphoblastic leukemia (ALL)].
    Krawczuk-Rybak M; Kitszel A; Kaliszewski J; Wołczyński S
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2003; 9(1):35-40. PubMed ID: 12831636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Ifversen M
    Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters?
    Schmiegelow K; Schrøder H; Schmiegelow M
    Cancer Chemother Pharmacol; 1994; 34(3):209-15. PubMed ID: 8004753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between insulin-like growth factors (IGF-I and IGF-II), IGF-binding proteins (IGFBP-3, IGFBP-2), leptin and anthropometric parameters (height, body mass index) during antileukaemic treatment in children.
    Krawczuk-Rybak M; Muszyńska-Rosłan K; Kitszel A; Sawicka-Zukowska M; Wołczyński S
    Rocz Akad Med Bialymst; 2005; 50():208-11. PubMed ID: 16358968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia.
    Mohnike KL; Kluba U; Mittler U; Aumann V; Vorwerk P; Blum WF
    Eur J Pediatr; 1996 Feb; 155(2):81-6. PubMed ID: 8775218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifications of growth velocity and the insulin-like growth factor system in children with acute lymphoblastic leukemia: a longitudinal study.
    Argüelles B; Barrios V; Pozo J; Muñoz MT; Argente J
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4087-92. PubMed ID: 11095437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-Thioguanine nucleotide accumulation in red blood cells during maintenance chemotherapy for childhood acute lymphoblastic leukemia, and its relation to leukopenia.
    Schmiegelow K; Bruunshuus I
    Cancer Chemother Pharmacol; 1990; 26(4):288-92. PubMed ID: 2369793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
    Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
    Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K; Bretton-Meyer U
    Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in concentrations of circulating insulin-like growth factors I and II and binding proteins BP-2 and BP-3 in children treated for acute lymphoblastic leukaemia].
    Krawczuk-Rybak M; Kitszel A; Wołczyński S
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(1):15-20. PubMed ID: 15355735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of economic status on height, insulin-like growth factor (IGF)-I and IGF binding protein-3 concentrations in healthy Turkish children.
    Turan S; Bereket A; Furman A; Omar A; Berber M; Ozen A; Akbenlioglu C; Haklar G
    Eur J Clin Nutr; 2007 Jun; 61(6):752-8. PubMed ID: 17164829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum concentrations of insulin-like growth factors (IGF)-I and IGF-II and IGF binding proteins (IGFBP)-2 and IGFBP-3 in 49 children with ALL, NHL or solid tumors].
    Mohnike K; Kluba U; Blum WF; Aumann V; Vorwerk P; Mittler U
    Klin Padiatr; 1995; 207(4):225-9. PubMed ID: 7564158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of serum growth factors (IGF-I,-II and IGFBP-2,-3) prior to and after stem cell transplantation in children with acute leukemia.
    Dawczynski K; Kauf E; Zintl F
    Bone Marrow Transplant; 2003 Aug; 32(4):411-5. PubMed ID: 12900778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.
    Andersen JB; Szumlanski C; Weinshilboum RM; Schmiegelow K
    Acta Paediatr; 1998 Jan; 87(1):108-11. PubMed ID: 9510461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.